Loading…

Pharmacological Profile and Molecular Modeling of Cyclic Opioid Analogues Incorporating Various Phenylalanine Derivatives

Peptide‐based agonists of the μ opioid receptor (μOR) are promising therapeutic candidates for pain relief with reduced side effects compared to morphine. A deep understanding of μOR–ligand interactions is necessary for future design of peptide‐based opioid analgesics. To explore the requirements of...

Full description

Saved in:
Bibliographic Details
Published in:ChemMedChem 2020-07, Vol.15 (14), p.1322-1329
Main Authors: Adamska‐Bartłomiejczyk, Anna, Lipiński, Piotr F. J., Piekielna‐Ciesielska, Justyna, Kluczyk, Alicja, Janecka, Anna
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Peptide‐based agonists of the μ opioid receptor (μOR) are promising therapeutic candidates for pain relief with reduced side effects compared to morphine. A deep understanding of μOR–ligand interactions is necessary for future design of peptide‐based opioid analgesics. To explore the requirements of the μOR binding pocket, eight new analogues of our cyclic peptide Tyr‐c[d‐Lys−Phe−Phe−Asp]NH2 displaying high μOR affinity were synthesized, in which Phe in either the third or fourth position was replaced by various derivatives of this amino acid (β3‐Phe, homoPhe, β3‐homoPhe and PhGly). The aim of this research was to examine the structural effects of such modifications on the bioactivity, and both experimental and theoretical methods were used. The binding of the cyclic analogues to all three OR types (μ, δ, κ) was assessed by radioligand competitive binding assay, and their functional activity was determined in a calcium mobilization assay. In order to provide structural hypotheses explaining the obtained experimental affinities, the complexes of the cyclic peptides with μOR were subjected to molecular modeling. Location, location: Incorporating phenylalanine derivatives has helped to establish pharmacophoric requirements for positions 3 and 4 in the cyclic opioid ligand Tyr‐c[d‐Lys−Phe−Phe−Asp]NH2. For example, an additional methylene does not significantly affect binding at position 4, whereas it has a relatively strong effect at position 3. These results will be useful for the design of peptide‐based opioid analgesics.
ISSN:1860-7179
1860-7187
DOI:10.1002/cmdc.202000248